Paloma Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Paloma Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-14,730	Closed	-$293K	–	450
2024 Q3	$293K	Buy	+14,730	New	+$273K	0.01%	815
2019 Q4	–	Sell	-54,502	Closed	-$289K	–	2200
2019 Q3	$289K	Buy	+54,502	New	+$290K	0.01%	1547
2019 Q1	–	Sell	-15,740	Closed	-$30K	–	1721
2018 Q4	$30K	Buy	+15,740	New	+$45.1K	﹤0.01%	1182
2016 Q3	–	Sell	-282,261	Closed	-$200K	–	1880
2016 Q2	$200K	Buy	+282,261	New	+$227K	﹤0.01%	1970
2016 Q1	–	Sell	-20,372	Closed	-$50K	–	1876
2015 Q4	$50K	Buy	+20,372	New	+$58.3K	﹤0.01%	1644
2014 Q4	–	Sell	-71,994	Closed	-$239K	–	1175
2014 Q3	$239K	Buy	+71,994	New	+$188K	0.01%	796

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Paloma Partners's CPRX Position: Q4 2024 in Review

Paloma Partners sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 14,730 shares — an estimated $293K sold.

Paloma Partners first reported a position in CPRX in Q3 2014 and held it in 6 quarters. The position peaked at $293K in Q3 2024. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

Paloma Partners reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
Paloma Partners sold 14,730 Catalyst Pharmaceutical shares in Q4 2024, an estimated $293K.
Paloma Partners first reported a position in Catalyst Pharmaceutical in Q3 2014 and held it in 6 quarters.
Paloma Partners's Catalyst Pharmaceutical position peaked at $293K in Q3 2024.
336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.